The Pharmacokinetics of a Hemp-Based Topical Cannabinoid Product in a Sanitized and Controlled Environment
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Change in concentration of oral fluid cannabinoids
研究概览
简要总结
This study will evaluate the pharmacokinetic effects of acute and chronic dosing of a hemp-based cannabidiol (CBD) topical lotion with low levels of delta-9-tetrahydrocannabinol (THC) in a sanitized and controlled environment.
详细描述
Participants (N = 6) will complete an 7-day residential study using a high CBD/low D9-THC lotion. The lotion is applied to the participants' upper arms four times daily in a sanitized and controlled procedure that eliminates the potential for specimen contamination. Oral fluid (OF) is collected before and after application (six samples/day); blood and urine are collected once/day. On discharge day, participants provide an intentionally contaminated OF sample. Participants return after a 7-day washout to provide 4 additional OF specimens, one "clean" and three more intentionally contaminated samples over a two-hour course.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Have provided written informed consent
- •Be between the ages of 18 and 55
- •Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests
- •Test negative for recent cannabis use in urine at the screening visit and again upon admission for the inpatient stay.
- •Test negative for other drugs of abuse, including alcohol, at the screening visit and again upon admission for the inpatient stay.
- •Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at each study visit.
- •Have a body mass index (BMI) in the range of 18 to 38 kg/m2
- •Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg
- •Report prior experience using cannabis or CBD products.
排除标准
- •Non-medical use of psychoactive drugs other than, nicotine, alcohol, or caffeine in the month prior to the screening visit.
- •History of or current evidence of significant medical or psychiatric illness judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures.
- •Current use of medications which, in the opinion of the investigator or medical monitor, will interfere with the study results or the safety of the subject.
- •History of xerostomia (dry mouth), or the presence of mucositis, gum infection or bleeding, or other significant oral cavity disease or disorder that in the investigator's opinion may affect the collection of oral fluid samples.
- •Known allergy to any ingredients in the study drug.
- •Enrolled in another clinical trial or have received any drug as part of a research study within 30 days prior to dosing.
研究组 & 干预措施
Topical CBD Product with low level of THC
Participants will topically apply a high CBD-product that also contains low levels of THC.
干预措施: CBD (Drug)
Topical CBD Product with low level of THC
Participants will topically apply a high CBD-product that also contains low levels of THC.
干预措施: THC (Drug)
结局指标
主要结局
Change in concentration of oral fluid cannabinoids
时间窗: Days 1-7 and Day 14
Concentration of cannabinoids will be measured in oral fluid (unit of measurement: nanograms/mL)
次要结局
- Change in concentration of blood cannabinoids(Days 1-7 and Day 14)
- Change concentration of urine cannabinoids(Days 1-7 and Day 14)
- Change in the number of total minutes of sleep(Days 1-7)